Unaudited Financial Results for the quarter ended on June 30, 2026.

Q1FY27 results (unaudited): Standalone: Revenue 0.555bn -41% y-y (0.944bn) EBITDA 0.068bn -56% y-y (0.153bn) EBITDA margin 12.3% (16.2%) -390 bps y-y PAT 0.037bn -63% y-y (0.100bn) Consolidated: Revenue 0.937bn -19% y-y (1.160bn) EBITDA 0.085bn -38% y-y (0.138bn) EBITDA margin 9.1% (11.9%) -280 bps y-y PAT -0.036bn (loss) vs -0.009bn loss y-y FY26 results (audited): Standalone: Revenue 2.340bn EBITDA 0.211bn EBITDA margin 9.0% PAT 0.160bn Consolidated: Revenue 3.454bn EBITDA 0.253bn EBITDA margin 7.3% PAT -2.731bn (loss) Dividend: None stated Commentary: Q1FY27 standalone revenue declined 41% y-y due to a high base effect from a large institutional order in Q1FY26. EBITDA margin contracted due to lower volumes despite improved gross margin. Subsidiaries Innoxel Lifesciences and Varenyam Healthcare showed strong revenue growth and margin improvement, with Innoxel ramping up commercial supply in Q2FY27. Consolidated loss narrowed sequentially with improved EBITDA and lower finance costs. FY27 guidance reaffirmed with growth expected in later quarters.